Trials / Completed
CompletedNCT01058291
Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500
Phase 3 Study of KW-6500 (Placebo-Controlled Double-Blind Crossover Comparative Study in Patients With Parkinson's Disease)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a placebo-controlled double-blind crossover comparative study of KW-6500 in Parkinson's disease patients with motor response complications on levodopa therapy. The efficacy of KW-6500 is evaluated using the change of UPDRS part III score at double blind period after 12 weeks subcutaneous self-injections.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KW-6500 | Twelve weeks subcutaneous injection of 1 to 6 mg for the OFF state |
| DRUG | KW-6500 Placebo | Twelve weeks subcutaneous injection for the OFF state |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2010-10-01
- Completion
- 2010-10-01
- First posted
- 2010-01-28
- Last updated
- 2017-03-03
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01058291. Inclusion in this directory is not an endorsement.